P69 | REAL-WORLD USAGE OF HYALURONIDASE-FACILITATED SUBCUTANEOUS IMMUNOGLOBULIN 10% IN PATIENTS WITH MULTIPLE MYELOMA DIAGNOSED WITH SECONDARY IMMUNODEFICIENCY: AN INTERIM ANALYSIS

Patients with multiple myeloma (MM) are susceptible to secondary immunodeficiency (SID) owing to both their underlying disease and/or immunosuppressive therapy. HyMMy (NCT05879757) is an ongoing, prospective, non-interventional, observational study of hyaluronidase-facilitated subcutaneous immunogl...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	E. Kastritis, S. Sánchez-Ramón, A.G. Szabo, B. Machalinski, A. Pérez-Montaña, J. Chen, B. Mc Coy, M. Kamieniak, S. Wietek
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	Ferrata Storti Foundation 2026-04-01
Sarja:	Haematologica
Linkit:	https://haematologica.org/article/view/14073
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!